Healthcare · NSE: STAR
Strides Pharma Science
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 30 Oct 2026 · Read the filing on NSEFiling
- M.Cap
- ₹9,089Cr
- P/E
- 14.7×
- 1Y return
- +4.51%
- From 52W high
- −21.8%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 1,430 | 1,221 | +17.1% | 1,265 | +13.0% |
| EBITDA | 251 | 232 | +8.4% | 230 | +9.2% |
| EBITDA margin | 17.6% | 19.0% | -142 bps | 18.2% | -61 bps |
| One-off items | -2 | -9 | — | 63 | — |
| PBTProfit before tax | 150 | 154 | -3.0% | 201 | -25.6% |
| Net profit | 131 | 128 | +2.6% | 157 | -16.6% |
| EPS (₹) | 14.19 | 13.84 | +2.5% | 17.02 | -16.6% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
Overall FY28 growth aspiration remains intact
Badree Komandur · MD & Group CEO · p. 3
Overall FY28 growth aspiration remains intact
“Let me share the headlines first. Our overall FY '28 growth aspiration remains intact. Our rest of the business is accelerating faster than the U.S. and well ahead of the schedule.”
H2 expected to be stronger than H1
Badree Komandur · MD & Group CEO · p. 3
H2 expected to be stronger than H1
“As we highlighted last quarter, we expect H2 to be stronger than H1.”
US: Better H2 expected for US business
Badree Komandur · MD & Group CEO · p. 6
US: Better H2 expected for US business
“Overall, we expect a better H2 for the US business.”
H1 gross margins expected to be sustained as cost increases moderate
Vikesh Kumar · Group CFO · p. 8
H1 gross margins expected to be sustained as cost increases moderate
“With cost increases now moderating and our cost improvement programs, including alternate sourcing and procurement initiatives gaining traction, we are confident of sustaining our H1 gross margins going forward.”
Net debt-to-EBITDA expected to stabilise and improve by year end
Vikesh Kumar · Group CFO · p. 9
Net debt-to-EBITDA expected to stabilise and improve by year end
“With this, we expect our net debt-to-EBITDA ratio to stabilize and improve by the end of the year.”
More figures from the call
“So we expect to launch 4 to 6 products. But more importantly, the products that we already launched will also see revenues in H2.”
“INR43 crores. So it will be within that INR40 crores to INR45 crores range.”
“At the same time, we continue to invest in our future, deploying INR208 crores in capex and intangibles to support our growth platforms.”
“So the difference between the INR200 crores and the INR260 crores is the INR60 crores of payments were for all the investments that were done last year.”
“We have more than 40 value-accretive products in our active pipeline, with filings and approvals planned in a phased manner and commercialisation through FY30.”
“we have more than 10 CS products in our pipeline across multiple domains, including nasal sprays, patches and films, which will expand our addressable market to around $4.5 billion, about six times the market we serve today.”
In short
- 01US revenue aspiration of about $375 million now expected a little beyond FY28; overall FY28 growth aspiration kept.
- 02Ex-US revenue reached 102% of US revenue in Q2 FY27; Ex-US FY28 revenue expected upwards of $375 million.
- 03Q2 FY27 revenue was Rs 14,297 million, up 17% year-on-year; EBITDA margin 17.6% on higher material and freight costs.
- 04Gross margin expected around 58%, in a 58% to 60% range, after 56% in Q2.
- 05Net debt-to-EBITDA rose to 1.72x on working capital; expected to stabilise and improve by year end.
- 06Capex for FY27 expected around Rs 300 crore; FY28 slightly lower.
- 074 to 6 US launches expected in H2; first nasal spray approval expected in Q4; Sandoz deal expected to close in Q3.
Capex
FY28 capex may be slightly lower
Vikesh Kumar · Group CFO · Q&A · p. 13
FY28 capex may be slightly lower
“Yes. FY '28 can be slightly lower.”
Capex to cover maintenance and some intangibles
Vikesh Kumar · Group CFO · Q&A · p. 14
Capex to cover maintenance and some intangibles
“There is maintenance capex that continues. So it will be maintenance capex and then some parts to intangibles, yes.”
Capacity
Controlled Substances: Chestnut Ridge facility has capacity to make US-manufactured controlled substances
Badree Komandur · MD & Group CEO · p. 6
Controlled Substances: Chestnut Ridge facility has capacity to make US-manufactured controlled substances
“Regulations require these products to be manufactured in the US, and our Chestnut Ridge facility already has the capacity and expertise to do exactly that.”
Order book
US B2B: US B2B partner business had strong order book and new business wins
Badree Komandur · MD & Group CEO · p. 5
US B2B: US B2B partner business had strong order book and new business wins
“Our B2B partner business saw a strong order book, and we secured meaningful new business wins during the quarter, from a partnered product, our recent launches and other key molecules in our portfolio.”
Segments
Ex-US: Ex-US revenue reached 102% of US revenue in Q2 FY27
Badree Komandur · MD & Group CEO · p. 5
Ex-US: Ex-US revenue reached 102% of US revenue in Q2 FY27
“Ex-US was at 76% of the US in FY25 and 90% in FY26, and in Q2 FY27 it reached 102%, crossing the US well ahead of schedule.”
Ex-US: Continued margin expansion expected in Ex-US business
Badree Komandur · MD & Group CEO · p. 5
Ex-US: Continued margin expansion expected in Ex-US business
“With growing scale, operating leverage and a better portfolio mix, we also expect continued margin expansion in this business.”
US: US Q2 revenue Rs 6,855 million ($73 million), up 9% year-on-year and quarter-on-quarter
Badree Komandur · MD & Group CEO · p. 5
US: US Q2 revenue Rs 6,855 million ($73 million), up 9% year-on-year and quarter-on-quarter
“Revenue for Q2 stood at ₹6,855 million, or $73 million, growing 9% year-on-year and 9% quarter-on-quarter.”
US: US H1 revenue Rs 13,137 million, up 7%
Badree Komandur · MD & Group CEO · p. 5
US: US H1 revenue Rs 13,137 million, up 7%
“For H1, US revenue was ₹13,137 million, up 7% year-on-year.”
US: New US wins to show up in coming quarters and support better H2
Badree Komandur · MD & Group CEO · p. 5
US: New US wins to show up in coming quarters and support better H2
“These wins will begin to show up in our performance over the coming quarters and underpin the better H2 we have been talking about.”
Demand
Ex-US: Q2 delivered without spillovers; Ex-US demand and order books healthy
Badree Komandur · MD & Group CEO · p. 6
Ex-US: Q2 delivered without spillovers; Ex-US demand and order books healthy
“with robust supply chain execution, we delivered Q2 without any spillovers, and demand and order books across our key Ex-US markets remain healthy.”
US: Oral product shortages now minimal as industry supply and approvals improved
Vikesh Kumar · Group CFO · Q&A · p. 16
US: Oral product shortages now minimal as industry supply and approvals improved
“The number of regulatory approvals have improved and which is effectively what has led is very minimal shortages across most of the oral products that are there.”
US: US shortages now mainly in injectables and patches
Vikesh Kumar · Group CFO · Q&A · p. 16
US: US shortages now mainly in injectables and patches
“I mean the shortages that we see are either in injectables or in patches that continue to have shortages.”
Margins and costs
Gross margin 56.0% vs 57.8% a year ago and 60.9% in Q1, on higher input costs
Badree Komandur · MD & Group CEO · p. 4
Gross margin 56.0% vs 57.8% a year ago and 60.9% in Q1, on higher input costs
“Gross margin stood at 56.0%, compared with 57.8% in Q2 last year and 60.9% in Q1, reflecting higher input costs linked to the geopolitical situation.”
EBITDA margin 17.6% vs 19.0% a year ago, on higher material, freight and logistics costs
Badree Komandur · MD & Group CEO · p. 4
EBITDA margin 17.6% vs 19.0% a year ago, on higher material, freight and logistics costs
“EBITDA margin was 17.6%, compared with 19.0% in Q2 last year and 18.2% in Q1, as we absorbed higher material, freight and logistics costs linked to the same geopolitical situation.”
Cost pressures addressed through alternate sourcing, procurement and cost optimisation
Badree Komandur · MD & Group CEO · p. 4
Cost pressures addressed through alternate sourcing, procurement and cost optimisation
“We are actively addressing these cost pressures through alternate sourcing, procurement initiatives and continuous cost optimisation across the business, and we are confident in our ability to manage them.”
US: US operating costs higher; products below margin profile not launched
Badree Komandur · MD & Group CEO · p. 4
US: US operating costs higher; products below margin profile not launched
“Second, operating costs are higher, with increased material costs and our decision to hold more inventory to sustain our industry-leading service levels. We also chose not to launch products that did not meet our margin profile, to protect profitability.”
Material costs rose to 44% of revenue from 42.2%
Vikesh Kumar · Group CFO · p. 8
Material costs rose to 44% of revenue from 42.2%
“Our material costs rose to 44% of revenues in Q2 from 42.2% last year, reflecting the increase in raw material costs that Badree described.”
Debt and working capital
Net finance cost Rs 43 crore, higher on working capital borrowings
Vikesh Kumar · Group CFO · p. 8
Net finance cost Rs 43 crore, higher on working capital borrowings
“net finance cost was at INR43 crores, slightly higher due to the higher average working capital borrowings we had during the quarter.”
Net debt-to-EBITDA 1.72x after Rs 211 crore rise in net debt in H1
Vikesh Kumar · Group CFO · p. 9
Net debt-to-EBITDA 1.72x after Rs 211 crore rise in net debt in H1
“The ratio now stands at 1.72x, reflecting the INR211 crores increase in net debt during H1, driven by working capital.”
Cash-to-cash cycle 137 days, up 13 days; working capital up Rs 307 crore in H1
Vikesh Kumar · Group CFO · p. 9
Cash-to-cash cycle 137 days, up 13 days; working capital up Rs 307 crore in H1
“Our cash-to-cash cycle stood at 137 days. This is up 13 days from March 2026 with absolute working capital increasing by INR307 crores during the first half.”
About Rs 174 crore of working capital rise from 14-day inventory increase
Vikesh Kumar · Group CFO · p. 9
About Rs 174 crore of working capital rise from 14-day inventory increase
“Approximately INR174 crores reflects the 14 days increase, which we have seen in our inventory levels from Q4.”
Cash conversion cycle to improve in coming quarters
Badree Komandur · MD & Group CEO · Q&A · p. 12
Cash conversion cycle to improve in coming quarters
“Cash conversion cycle definitely will improve in the coming quarters.”
Acquisitions and new business
US: Three US products launched in quarter; commercialised portfolio at 75
Badree Komandur · MD & Group CEO · p. 5
US: Three US products launched in quarter; commercialised portfolio at 75
“During the quarter, we launched three products, taking our commercialised portfolio to 75 products, up from”
Nasal sprays: Third nasal spray, a controlled substance, filed in September 2026
Badree Komandur · MD & Group CEO · p. 6
Nasal sprays: Third nasal spray, a controlled substance, filed in September 2026
“as committed on our last call, we filed our third nasal spray, also a controlled substance, in September 2026.”
Nasal sprays: First nasal spray approval expected in Q4
Badree Komandur · MD & Group CEO · p. 6
Nasal sprays: First nasal spray approval expected in Q4
“Our first nasal spray has a GDUFA goal date in H2 FY27, and we expect approval in Q4.”
Transdermal Patches: Controlled-substance patch relaunch expected in Q3; full-year benefit in FY28
Badree Komandur · MD & Group CEO · p. 6
Transdermal Patches: Controlled-substance patch relaunch expected in Q3; full-year benefit in FY28
“In Transdermal Patches, we expect to relaunch a controlled-substance patch in Q3. This product came to us as part of the ANDAs we acquired from Endo, and we expect its full-year benefit to flow into FY28.”
Africa: Sandoz deal awaiting antitrust approval in a few countries; close expected in Q3
Badree Komandur · MD & Group CEO · p. 7
Africa: Sandoz deal awaiting antitrust approval in a few countries; close expected in Q3
“Our deal with Sandoz is now awaiting antitrust approval in only a few countries, and we expect it to close in Q3.”
Management
Biren Gabhawala joins Board as Independent Director
Badree Komandur · MD & Group CEO · p. 7
Biren Gabhawala joins Board as Independent Director
“We are very pleased to welcome Mr. Biren Gabhawala to our Board as an Independent Director.”
One-offs
H1 reported PAT Rs 300 crore, up 26.4%, includes Pivot Path divestment gain
Vikesh Kumar · Group CFO · p. 9
H1 reported PAT Rs 300 crore, up 26.4%, includes Pivot Path divestment gain
“Reported PAT for the first half was at INR300 crores, which was up 26.4% and this included the gain on Pivot Path divestment, which we recognized in Q1.”
About Rs 170 crore of H1 working capital rise from geopolitical disruptions, called one-off
Vikesh Kumar · Group CFO · Q&A · p. 14
About Rs 170 crore of H1 working capital rise from geopolitical disruptions, called one-off
“The increase in our working capital in the first half has been about INR300 crores and almost INR170 crores of it was on account of the geopolitical disruptions, which was more like a one-off.”
Risks
Controlled Substances: Controlled Substances growth constrained by quota allocations, expected to improve
Badree Komandur · MD & Group CEO · p. 4
Controlled Substances: Controlled Substances growth constrained by quota allocations, expected to improve
“And third, growth in Controlled Substances is constrained by quota allocations, which we expect to improve progressively.”
Other
Q2 FY27 revenue Rs 14,297 million, up 17% year-on-year
Badree Komandur · MD & Group CEO · p. 3
Q2 FY27 revenue Rs 14,297 million, up 17% year-on-year
“Revenue for Q2 FY27 reached ₹14,297 million, our highest ever, growing 17% year-on-year”
Ex-US: Ex-US about 49% of revenue, up from 43% a year earlier
Badree Komandur · MD & Group CEO · p. 4
Ex-US: Ex-US about 49% of revenue, up from 43% a year earlier
“Ex-US now contributes about 49% of our revenues, up from 43% in Q2 last year, a clear sign that our diversification strategy is delivering.”
EBITDA grew 8% to Rs 2,509 million
Badree Komandur · MD & Group CEO · p. 4
EBITDA grew 8% to Rs 2,509 million
“EBITDA grew 8% year-on-year to ₹2,509 million, crossing the ₹2,500 million mark in a single quarter for the first time, another milestone for Strides.”
Operational PAT up 12% to Rs 1,358 million; operational EPS Rs 14.7
Badree Komandur · MD & Group CEO · p. 4
Operational PAT up 12% to Rs 1,358 million; operational EPS Rs 14.7
“Operational PAT grew a strong 12% year-on-year to ₹1,358 million, and Operational EPS rose to ₹14.7, from ₹13.2 in Q2 last year.”
Over ten quarters revenue compounded about 14%, EBITDA 13%, operational PAT 41%
Badree Komandur · MD & Group CEO · p. 4
Over ten quarters revenue compounded about 14%, EBITDA 13%, operational PAT 41%
“Revenue has compounded at about 14%, EBITDA at about 13%, and operational PAT at about 41%.”
Sources
- Earnings call transcript, Q2 FY27 Filed 2 Nov 2026 · 17 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

